GPC2 CAR T cells

Phase 1Cell therapy

SStanford University

GPC2 CAR T cells is one of 24 biologic programs targeting Refractory Neuroblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory NeuroblastomaEnrolling by invitation

MedulloblastomaRecruiting

Refractory NeuroblastomaPhase 1

Enrolling by invitation

MedulloblastomaPhase 1

Recruiting

Competition

Competitive Landscape

32 competitors in Medulloblastoma

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Oncovin

9 3

Oncovin

Eli Lilly

Phase 3

6 4

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Bicnu

Cytoxan

BBaxter Healthcare Corporation

Phase 3

14 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

13 8

Ceenu

AAzurity Pharmaceuticals

Phase 3

9 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

6 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Medulloblastoma

NCT07087002

Clinical

Trials by Indication[1]

Medulloblastoma1 trial

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Recruiting·SStanford University·Phase 1·NCT07087002·18 enrolled

Refractory Neuroblastoma1 trial

Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Enrolling by invitation·SStephan Grupp MD PhD·Phase 1·NCT05650749·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GPC2 CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GPC2 CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GPC2 CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SStanford University

GPC2 CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Medulloblastoma1 trial

Refractory Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News